Sicras-Mainar A, et al. - The purpose of this study was to analyze the use of resources and costs associated with the addition of an antimuscarinic (AM) in patients receiving an alpha-adrenergic-blocker (AAB) for the treatment of lower urinary tract symptoms (LUTS) linked to benign prostatic hyperplasia (BPH). Results revealed that the addition of an AM agent in patients treated for LUTS with AAB offered a lower use of healthcare resources in terms of the number of medical visits and concomitant medications required. Hence, reduced the overall costs of the healthcare system.